Ondine Biomedical reported a loss of $321,000 on revenues of $336,000 for the third quarter of 2010 (end-September 30), compared with a loss of $1.58 million on revenues of $173,000 for the same quarter a year ago.
"Despite continued challenging economic conditions, Ondine experienced continued growth and partner interest across all our business sectors during the third quarter of 2010," stated Carolyn Cross, chairman and CEO, in a press release.
Sales during the first nine months of 2010 consisted of the company's Periowave photodisinfection product to Ondine's dental business partner, Periowave Dental Technologies, under a manufacturing and supply agreement entered into in June 2009.
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
